Last reviewed · How we verify

JTA-004 — Competitive Intelligence Brief

JTA-004 (JTA-004) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allogeneic cell therapy. Area: Orthopedics / Bone Regeneration.

phase 3 Allogeneic cell therapy Orthopedics / Bone Regeneration Small molecule Live · refreshed every 30 min

Target snapshot

JTA-004 (JTA-004) — Bone Therapeutics S.A. JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
JTA-004 TARGET JTA-004 Bone Therapeutics S.A phase 3 Allogeneic cell therapy
Allogenix Plus Allogenix Plus University of Missouri-Columbia marketed Allogeneic cell therapy
Deramiocel (CAP-1002) Deramiocel (CAP-1002) Capricor Inc. phase 3 Allogeneic cell therapy
NiCord® (omidubicel) NiCord® (omidubicel) Gamida Cell ltd phase 3 Allogeneic cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allogeneic cell therapy class)

  1. Capricor Inc. · 2 drugs in this class
  2. Aivita Biomedical, Inc. · 1 drug in this class
  3. Bone Therapeutics S.A · 1 drug in this class
  4. Gamida Cell ltd · 1 drug in this class
  5. University of Missouri-Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JTA-004 — Competitive Intelligence Brief. https://druglandscape.com/ci/jta-004. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: